Trial · NCT07013240
Botulinum Toxin Injection After Sternotomies to Improve Scar Aspect and Impact
NCT07013240, Phase 3, Not yet recruiting, University Hospital, Bordeaux
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Botulinum Toxin Injection After Sternotomies to Improve Scar Aspect and Impact. Trials, record NCT07013240. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07013240
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Botulinum Toxin Injection After Sternotomies to Improve Scar Aspect and Impact
- NCT number
- NCT07013240
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 50 participants, estimated
- Lead sponsor
- University Hospital, Bordeaux
- Conditions
- Sternotomy Closure,Open Heart Surgery
- Interventions
- Botulinum toxin injection
- First posted
- 2025-06-10
- Last updated
- 2025-06-10
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of Stony Brooke Scar Scale score | Month 6 | The Stony Brook Scar Evaluation Scale (SBSES) was developed by Singer et al. in 2007. It is based on five scar indicators: width, elevation or depression, color, suture or staple marks, and overall appearance.Each indicator is assigned a score between 0 and 5 points. These scores are totaled to obtain the final score between 0 and 5 points. This score will be determined for each half of scar (superior part and inferior part). |
| Secondary | Measure of scar width in millimeters | Month 3, month 6, month 12 and month 18 | |
| Secondary | Evaluation of scar with POSAS : observer scale | Month 3, month 6, month 12 and month 18 | The observer's POSAS scale comprises six parameters (vascularity, pigmentation, thickness, relief, elasticity and surface). Each parameter is rated on a scale from 1 ("normal skin") to 10 ("worst scar imaginable"). The sum of the six parameters constitutes the observer's total POSAS score scale . In addition, a general opinion is scored from 1 to 10. All parameters should preferably be compared to normal skin on a comparable a comparable anatomical region. This scale will be determined for each half of scar (superior part and inferior part). |
| Secondary | Evaluation of scar with The Physician's Global Assesment (PGA) | Month 3, Month 6, Month 12 and Month 18 | The Physician's Global Assesment (PGA) evaluates the scar based on whether it is considered an Invisible scar ; a Scar as fine as a pencil line, of a color similar to the adjacent skin ; a Visible scar, little infiltrated or flat, discreetly colored ; a Widened and infiltrated scar, visible suture lines, of a color contrasting with the skin ; a Hypertrophic scar, raised, hypervascularized or very hyperpigmented ; a Keloid. This evaluation will be determined for each half of scar (superior part and inferior part). |
| Secondary | Evaluation of Stony Brooke Scar Scale score | Month 3, Month 12 and Month 18 | The Stony Brook Scar Evaluation Scale (SBSES) was developed by Singer et al. in 2007. It is based on five scar indicators: width, elevation or depression, color, suture or staple marks, and overall appearance. Each indicator is assigned a score between 0 and 1 point. These scores are totaled to obtain the final score between 0 and 5 points. This scale will be determined for each half of scar (superior part and inferior part). |
| Secondary | Evaluation of scar with POSAS : Patient scale | Month 3, Month 6, Month 12 and Month 18 | The patient's POSAS scale comprises six parameters (pain, itching, color, stiffness, thickness and irregularity). Each parameter is rated on a scale from 1 ("normal skin") to 10 ("worst scar imaginable"). In addition, a general opinion is scored from 1 to 10. The sum of all these parameters constitutes the patient's total POSAS score scale. All parameters should preferably be compared to normal skin on a comparable a comparable anatomical region. This evaluation will be determined for each half of scar (superior part and inferior part). |
| Secondary | Satisfaction numerical scale | Month 3, Month 6, Month 12 and Month 18 | Scar satisfaction is rated on a scale from 0 ("not at all satisfied") to 10 ("extremely satisfied"). This scale will be determined for each half of scar (superior part and inferior part). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 18090752 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07013240
GET https://conductscience.org/api/trials/v1/NCT07013240/registered